Skipping surgery pays off for rectal cancer patients. A post-hoc analysis of two phase 2 trials found that locally advanced rectal cancer patients who achieved complete clinical response after total neoadjuvant therapy and opted for watch-and-wait had significantly better quality of life than those who underwent total mesorectal excision — with benefits lasting up to 5 years across physical, social, and bowel function domains.
For patients with locally advanced rectal cancer who achieve a complete clinical response (cCR) after total neoadjuvant therapy, skipping surgery may be the better long-term choice. A post-hoc analysis of two prospective phase 2 trials — published in JAMA Network Open — found that a watch-and-wait approach delivered statistically significant and clinically meaningful quality of life (QOL) advantages over total mesorectal excision (TME) across multiple domains over 5 years of follow-up.
The study drew on data from 385 patients treated across 19 German centers between 2015 and 2020. Of these, 56 were assigned to watch-and-wait after achieving cCR, while 329 underwent immediate TME. Even among patients who remained disease-free throughout follow-up, watch-and-wait continued to outperform surgery.
Key Takeaways:
Why it matters: Surgery for rectal cancer carries lasting functional consequences. These findings — though from non-randomized trials — offer compelling evidence that organ preservation is a viable, QOL-preserving strategy for carefully selected patients, and can meaningfully guide shared decision-making between clinicians and patients.
